Variables that Might Affect the Outcome of Immune Tolerance Therapy in Haemophiliacs with Factor VIII Inhibitors

S Ehrenforth; W Kreuz; M Funk; G Auerswald; I Scharrer

doi:10.1055/s-0038-1648960

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1994; 72(05): 784-785
DOI: 10.1055/s-0038-1648960

Letter to the Editor

Schattauer GmbH Stuttgart

Variables that Might Affect the Outcome of Immune Tolerance Therapy in Haemophiliacs with Factor VIII Inhibitors

S Ehrenforth

¹Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany

,

W Kreuz

¹Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany

,

M Funk

¹Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany

,

G Auerswald

²Department of Paediatrics, Prof.-Hess-Hospital, Bremen, Germany

,

I Scharrer

¹Department of Paediatrics and Internal Medicine, University Hospital, Frankfurt am Main, Germany

› Author Affiliations

Abstract

PDF Download

PDF (163 kb)

References

References
1 Schwarzinger I, Pabinger I, Kominger C, Haschke F, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor FVIII concentrates. Am J Hematol 1987; 24: 241-245
1 Schwarz RS, Abildgaard CF, Aledort LM, Arkin S, Blom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ. Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1799-1805
3 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371
4 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
5 Brackmann HH. Induced immunotolérance in factor VIII inhibitor patients. Prog Clin Biol Res 1986; 150: 181-185
6 Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. and the Danish Study Group Continous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost 1987; 58: 1049
7 Kasper CK. Treatment of factor VIII inhibitors. Progr Hemostas Thromb 1989; 9: 57-86
8 Lusher JM. Factor VIII inhibitors. Etiology, characterisation, natural history and management. In: Factor VIII/vWF, platelet formation and function in health and disease. A tribute to Marion Barnhart I, Lusher JM, Mammen EF, McCoy L, Walz D. eds Ann NY Acad Sci; 1987. 509 089-102
9 Ewing NP. Induction of Immune Tolerance with Factor VIII Concentrate in Patients with Hemophilia A and Inhibitors. In: Recent Advances in Hemophilia Care Kasper CK. ed Alan R Liss Inc; NY: 1990. pp 59-68
10 Hedner U, Glazer S. Management of hemophilia patients with inhibitors. In: Coagulation disorders I 1992. 5 1035-1046
11 Mariani G, Ghirardini A, Bellocco R. Immune Tolerance in Hemophilia -Principal Results from the International Registry. Thromb Haemost 1994; 72: 155-158